title: Pharmacokinetic profile of meropenem, administered at 500 milligrams every 8 hours, in plasma and cantharidin-induced skin blister fluid.
abstract: The pharmacokinetic disposition of meropenem, administered at 500 mg every 8 h, in plasma and cantharidin-induced blister fluid is described. Peak meropenem concentrations in blister fluid lagged behind peak meropenem concentrations in plasma, while a lower elimination rate from blister fluid was also noted. The mean penetration of meropenem into blister fluid was 67%. The pharmacokinetic profile of meropenem in blister fluid supports the utility of this dose in the management of skin and soft tissue infections.
authors.affiliation: Center for Anti-Infective Research and Development, Division of Infectious Diseases, Office for Research, Hartford Hospital, Hartford, Connecticut 06102, USA.
authors.forename: Dana
authors.initials: D
authors.lastname: Maglio
authors.forename: Renli
authors.initials: R
authors.lastname: Teng
authors.forename: Per T
authors.initials: PT
authors.lastname: Thyrum
authors.forename: Charles H
authors.initials: CH
authors.lastname: Nightingale
authors.forename: David P
authors.initials: DP
authors.lastname: Nicolau
mesh_terms: D000328:Adult; D019540:Area Under Curve; D001768:Blister / Q000378:metabolism*; D002193:Cantharidin / Q000633:toxicity*; D004334:Drug Administration Schedule; D006207:Half-Life; D006801:Humans; D000077731:Meropenem; D013845:Thienamycins / Q000008:administration & dosage / Q000493:pharmacokinetics*
chemical_list: D013845:Thienamycins; D000077731:Meropenem; D002193:Cantharidin